Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$105.92
▼ $4.75 (-4.3%)
Market data updated: 09/19 06:30 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
Not available
Day Range
$104.75 - $112.32
52-Week Range
$61.96 - $150.44
Beta
—
Next Earnings
02.12.2026
Support
$87.96
Resistance
$150.44
BLLN is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-2.8% (1Y)
Strengths: 18/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 100.0%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $39.55 vs. price $105.92 (-62.7%)
Fair Value
Signal tension
Growth scores strong (82/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 0 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 0
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
57
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
1d ago · $110.67
Evidence: FOMO score jumped from 16 to 53 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
63
Value
33
Momentum
59
Risk
54
Sentiment
50
Fundamental
54
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **BillionToOne, Inc.** has centered on its expansion in molecular diagnostics, particularly the launch of its **Northstar Origin™** liquid biopsy test for identifying tissue-of-origin in cancer patients, alongside an expanded **Northstar Select®** gene panel. The company also gained positive analyst attention with a **Buy rating and $120 price target** from Canaccord Genuity, while CEO praise from **Jim Cramer** highlighted its potential despite valuation concerns. Additionally, a **co-founder sold shares worth $1 million**, though no broader financial or operational issues were reported.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about BillionToOne, Inc.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 3 vs. 3 out of the last 20 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
36
🎯 Conviction (vs. Emotion)
45
Psychology
64
Fundamentals
54
Technical
59
Valuation
33
The price rise has far outpaced the actual improvement in fundamental data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+1%
Market Narrative
74
Fundamental Reality
45
Narrative Gap
+29
🔀 Weak-Conviction Rally
Price is moving, but not accompanied by a matching rise in news attention/sentiment.
🧠 StockIQ Psychologist
The market’s dominant overconfidence (score 49) stems from a disconnect between price momentum (+4.0% ROC) and slower fundamental growth (+1.0% EPS), paired with a +150% DCF premium. Herding (score 47) suggests traders follow peers despite slight underperformance, while FOMO (16) is muted by neutral RSI and modest volume spikes. The key question: Is this overconfidence justified by improving fundamentals, or will it collapse if momentum stalls? Narrative-reality gap (14) hints at potential mispricing, but no clear trigger exists yet.
Updated: 09/09/2026, 07:26 AM
What could change this?
👥 What the crowd believes
"Canaccord Genuity analyst initiates coverage on BillionToOne with a Buy rating and announces Price Target of $120."
"Jim Cramer commented: 'it’s a pretty darn good company.'"
"BillionToOne announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction."
🧠 Market Brain events driving this
📈 11D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 23/100
🗣️ Why do they disagree?
Based on Walter Bagehot’s documented principles, the model estimates the stock has strong liquidity and would likely survive a credit squeeze, which is reflected in its perfect score. Quality‑ and growth‑oriented investors such as Philip Fisher, Charles Mackay, and Edgar Lawrence Smith assign scores in the 70‑range, indicating they view the company as high‑quality and a good long‑term hold, though they note no obvious crowd mania. More balanced or cycle‑aware frameworks like Jack Schwager, Morgan Housel, Peter Lynch, and Howard Marks hover around the 60‑point mark, suggesting the stock is holdable but with limited upside or already priced in. Value‑focused approaches, especially Benjamin Graham’s defensive and enterprising criteria and Samuel Armstrong Nelson’s cycle view, score below 35, implying the stock appears overvalued or overbought relative to their safety margins.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 75
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 67
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 65
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 63
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 62
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 61
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 59
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 57
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 52
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 51
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 50
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 30
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 23
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 217 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (7 bullish · 3 bearish · 3 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
68.3%
Operating Margin
5.3%
Net Margin
2.4%
EBITDA Margin
7.5%
ROE
1.6%
ROA
1.2%
ROIC
—
EPS
$0.18
Cash
$495.98M
Total Debt
$57.23M
Current Ratio
11.69
Debt/Equity
0.12
How is Fair Value calculated? →
Current Price
$105.92
Estimated Fair Value (DCF)
$39.55
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-62.7%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $19.64M | $18.02M |
| 2 | 19.4% | $23.45M | $19.74M |
| 3 | 13.8% | $26.67M | $20.60M |
| 4 | 8.1% | $28.84M | $20.43M |
| 5 | 2.5% | $29.56M | $19.21M |
Base FCF (last actual year)
$15.71M
Terminal Value
$466.15M
Present Value of Terminal Value
$302.96M
Enterprise Value
$400.96M
Net Debt
$-438.75M
Equity Value
$839.71M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$22.61
Tangible Book Value per Share (Tangible NAV)
$22.61
Sentiment based on basic keywords (not AI) — 3 positive, 14 neutral, 3 negative out of the last 20 articles.
Yahoo · 17.9.2026
Yahoo · 2.9.2026
PR Newswire · 2.9.2026
Benzinga · 2.9.2026
MT Newswires · 2.9.2026
MT Newswires · 1.9.2026
Yahoo · 1.9.2026
PR Newswire · 1.9.2026
Yahoo · 28.8.2026
Insider Monkey · 28.8.2026
Yahoo · 28.8.2026
Motley Fool · 28.8.2026
Benzinga · 27.8.2026
PR Newswire · 19.8.2026
PR Newswire · 18.8.2026
Benzinga · 18.8.2026
SeekingAlpha · 14.8.2026
Motley Fool · 12.8.2026
MT Newswires · 7.8.2026
SeekingAlpha · 7.8.2026
BillionToOne, Inc. (BLLN) currently has a StockIQ AI score of 57/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
BLLN currently scores 57/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, BLLN's estimated fair value is $39.55, which is 62.7% below the current price of $105.92. This is one valuation model among several signals in the fair-value category, not a price target.
BLLN's technical score is 59/100, which currently reads as neutral — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 100.0%; Earnings per share (EPS) growth: 103.4%; Free cash flow growth: 133.6%.
Based on the real signals StockIQ computed: Estimated fair value: $39.55 vs. price $105.92 (-62.7%); SMA 50 recently crossed below SMA 200; ATR: 5.6% of price.
StockIQ has no recorded dividend payment history for BLLN.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Tsao David | Gift | 8.9.2026 | 20,000 | -20,000 | — |
| Tsao David | Conversion of Derivative Security | 3.9.2026 | 20,000 | -20,000 | — |
| Tsao David | Conversion of Derivative Security | 3.9.2026 | 20,000 | +20,000 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 1,666 | +1,666 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 5,644 | +5,644 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 129,780 | -129,780 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 5,761 | +5,761 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 38,106 | +38,106 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 2,405 | +2,405 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 271,028 | -271,028 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 24,222 | -24,222 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 10,921 | -10,921 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 719 | +719 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 7,980 | +7,980 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 719 | +719 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 15,244 | +15,244 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 2,405 | -2,405 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 7,980 | -7,980 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 38,106 | -38,106 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 0 | -7,980 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 2,405 | +2,405 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 908,459 | -129,780 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 1,897,202 | -271,028 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 38,106 | +38,106 | — |
| KOLLURI KRISHNA KITTU | Other Transaction | 26.8.2026 | 169,550 | -24,222 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,348,604 shares short as of 2026-08-31 · vs. 1,920,601 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
61.1% of trading volume this week was short selling, vs. 65.3% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology